NCT05375734

Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Advanced Pulmonary Pleomorphic Carcinoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 32 (estimated)
• Sponsor: Second Affiliated Hospital of Nanchang University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the efficacy and safety of tislelizumab in combination with anlotinib in patients with stage III and IV PSC .

Detailed description

This is a single-arm, prospective, open phase II clinical study to evaluate the efficacy and safety of tislelizumab in combination with anlotinib in patients with stage III and Stage IV PSC. The primary endpoint of this study was Objective Response Rate (ORR).

Conditions

• Pulmonary Pleomorphic Carcinoma
• Immunotherapy
• Tislelizumab

Interventions

Type	Name	Description
DRUG	Tislelizumab in combination with anlotinib	Tislelizumab：200 mg，ivgtt，d1，Q3W anlotinib： 10mg P.O d1-d14, Q3W

Timeline

• Start date: 2021-08-17
• Primary completion: 2026-12-31
• Completion: 2026-12-31
• First posted: 2022-05-17
• Last updated: 2025-06-11

Locations

1 site across 1 country: China